MX2021000801A - Agonistas de il2. - Google Patents
Agonistas de il2.Info
- Publication number
- MX2021000801A MX2021000801A MX2021000801A MX2021000801A MX2021000801A MX 2021000801 A MX2021000801 A MX 2021000801A MX 2021000801 A MX2021000801 A MX 2021000801A MX 2021000801 A MX2021000801 A MX 2021000801A MX 2021000801 A MX2021000801 A MX 2021000801A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- polynucleotides
- polypeptides
- host cells
- amino acid
- Prior art date
Links
- 229940124753 IL-2 agonist Drugs 0.000 title 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract 6
- 102000055277 human IL2 Human genes 0.000 abstract 6
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 4
- 102000000588 Interleukin-2 Human genes 0.000 abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 210000003162 effector t lymphocyte Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invención se refiere a variantes de interleucina-2 (IL2). En una modalidad, las variantes de IL2 activan las células T efectoras sobre las células T reguladoras. En particular, la invención se refiere a un polipéptido que comprende una muteína de IL2 humana o una variante funcional de IL2 humana, en donde la IL2 humana o variante funcional de la misma se sustituye en al menos una posición que tiene un residuo de aminoácido ácido básico en la IL2 humana de tipo natural que hace contacto con la subunidad a del complejo del receptor ß? IL2 (IL2Raß?). Alternativamente, la muteína IL2 humana o de una variante funcional de la IL2 humana comprende al menos (i) una o más sustituciones de aminoácidos que reducen la afinidad para la subunidad alfa de ??_2?aß? y (ii) una o más sustituciones de aminoácidos que mejoran la afinidad para ??_2?ß?. La invención también se refiere a polinucleótidos que codician para los polipéptidos de la invención, células hospederas que comprenden los polinucleótidos, composiciones farmacéuticas que comprenden los polipéptidos, polinucleótidos o células hospederas, métodos terapéuticos o profilácticos de tratamiento que utilizan los polipéptidos, polinucleótidos, células hospederas o composiciones farmacéuticas y preparaciones médicas que comprenden los polipéptidos, polinucleótidos, células hospederas o composiciones farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018070068 | 2018-07-24 | ||
| PCT/EP2019/069541 WO2020020783A1 (en) | 2018-07-24 | 2019-07-19 | Il2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000801A true MX2021000801A (es) | 2021-04-12 |
Family
ID=67439198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000801A MX2021000801A (es) | 2018-07-24 | 2019-07-19 | Agonistas de il2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210292386A1 (es) |
| EP (1) | EP3827014A1 (es) |
| JP (2) | JP7550745B2 (es) |
| KR (1) | KR20210038549A (es) |
| CN (1) | CN112771072B (es) |
| AU (1) | AU2019311233B2 (es) |
| BR (1) | BR112021000811A8 (es) |
| CA (1) | CA3106858A1 (es) |
| IL (1) | IL280290A (es) |
| MX (1) | MX2021000801A (es) |
| SG (1) | SG11202013044PA (es) |
| WO (1) | WO2020020783A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
| WO2019028425A1 (en) | 2017-08-03 | 2019-02-07 | Synthorx, Inc. | Cytokine conjugates for the treatment of autoimmune diseases |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP7512210B2 (ja) * | 2018-09-21 | 2024-07-08 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 新規インターロイキン２およびその使用 |
| CN113874389A (zh) * | 2019-03-18 | 2021-12-31 | 生物技术细胞和基因治疗公司 | 用于特异性活化免疫效应细胞的白介素-2受体(il2r)和白介素-2(il2)变体 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| CA3147757A1 (en) | 2019-07-26 | 2021-02-04 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| MX2022002053A (es) | 2019-08-23 | 2022-03-17 | Synthorx Inc | Conjugados de il-15 y sus usos. |
| MX2022002740A (es) | 2019-09-10 | 2022-03-25 | Synthorx Inc | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. |
| EP4077397A2 (en) | 2019-12-20 | 2022-10-26 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| AU2021231869A1 (en) * | 2020-03-05 | 2022-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Designed IL-2 variants |
| CA3175728A1 (en) * | 2020-03-19 | 2021-09-23 | Innovent Biologics (Suzhou) Co., Ltd. | Interleukin-2 mutant and use thereof |
| US11746137B2 (en) * | 2020-03-31 | 2023-09-05 | Hanmi Pharm. Co., Ltd. | Immunostimulating IL-2 analogs |
| US11834485B2 (en) | 2020-04-21 | 2023-12-05 | Regeneron Pharmaceuticals, Inc. | IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof |
| CA3178074A1 (en) * | 2020-06-03 | 2021-12-09 | Nina Gunnarsson | Il-2 sequences and uses thereof |
| WO2022009123A1 (en) * | 2020-07-09 | 2022-01-13 | Eutilex Co., Ltd. | Il-2 variants |
| WO2022059794A1 (ja) * | 2020-09-18 | 2022-03-24 | 地方独立行政法人 宮城県立病院機構 | Ｉｌ－２変異体タンパク質及びこれを含む医薬 |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| CA3203977A1 (en) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| US20230303649A1 (en) | 2021-07-09 | 2023-09-28 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| CN118510795A (zh) * | 2022-01-07 | 2024-08-16 | 苏州克睿基因生物科技有限公司 | 新型白介素-2多肽 |
| KR20240164594A (ko) * | 2022-01-11 | 2024-11-19 | 아웃페이스 바이오, 인크. | 설계된 사이토카인 조성물 및 사용 방법 |
| WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| TW202409069A (zh) * | 2022-07-01 | 2024-03-01 | 大陸商北京星奇原生物科技有限公司 | Ｉｌ－２多肽和使用方法 |
| WO2024083097A1 (zh) * | 2022-10-19 | 2024-04-25 | 北京志道生物科技有限公司 | 一种il-2突变体 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
| WO2024094119A1 (zh) * | 2022-11-02 | 2024-05-10 | 北京昌平实验室 | 融合蛋白及其应用 |
| WO2024178000A2 (en) * | 2023-02-21 | 2024-08-29 | Sorrento Therapeutics, Inc. | Polynucleotides encoding modified interleukin 2 (il2) polypeptides, and methods of making and using the same |
| CN118620056A (zh) * | 2023-03-09 | 2024-09-10 | 北京天广实生物技术股份有限公司 | Il-2变体及其用途 |
| WO2024235281A1 (zh) * | 2023-05-17 | 2024-11-21 | 北京晶泰科技有限公司 | 白细胞介素-2变体及其应用 |
| CN119613562A (zh) * | 2023-09-14 | 2025-03-14 | 重庆精准生物技术有限公司 | 细胞因子融合蛋白及其应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| AU6113396A (en) * | 1995-06-14 | 1997-01-15 | Regents Of The University Of California, The | Novel high affinity human antibodies to tumor antigens |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| AU2003223683A1 (en) * | 2002-04-22 | 2003-11-03 | Georgetown University | Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| ES2343518T3 (es) * | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | Polipeptidos interferon alfa modificados resistentes a proteasas. |
| ES2551682T3 (es) | 2002-11-08 | 2015-11-23 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| US7569215B2 (en) * | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| CA2554089C (en) | 2004-02-09 | 2013-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| CA2557677A1 (en) * | 2004-03-05 | 2005-10-06 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| WO2008028977A2 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CA2583716A1 (en) * | 2007-04-18 | 2008-10-18 | Nautilus Biotech | Oral dosage formulations of protease resistant polypeptides |
| WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| US20100322930A1 (en) | 2007-12-27 | 2010-12-23 | Frank Kolbinger | Fibronectin-based binding molecules and their use |
| KR20110021832A (ko) | 2008-05-02 | 2011-03-04 | 노파르티스 아게 | 개선된 피브로넥틴기재 결합 분자 및 그의 용도 |
| CA2779073C (en) | 2009-10-30 | 2017-10-24 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| CN102939304B (zh) | 2010-04-09 | 2017-04-19 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
| WO2011130354A1 (en) | 2010-04-13 | 2011-10-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
| CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| EP2655409A4 (en) * | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2 |
| BR112013018932B1 (pt) | 2011-02-10 | 2020-11-17 | Roche Glycart Ag | polipeptídeo de interleucina-2 (il-2) mutante, imunoconjugado, polinucleotídeo isolado, célula hospedeira de microrganismos, método de produção de um polipeptídeo de il-2 mutante, composição farmacêutica e usos do polipeptídeo de il-2 mutante ou do imunoconjugado |
| WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| CA3093606A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
| CN106659757B (zh) | 2014-04-24 | 2022-01-28 | 利兰斯坦福初级大学董事会 | 白介素2的超级激动剂、部分激动剂和拮抗剂 |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2019
- 2019-07-19 EP EP19744656.0A patent/EP3827014A1/en active Pending
- 2019-07-19 US US17/262,097 patent/US20210292386A1/en active Pending
- 2019-07-19 JP JP2021503723A patent/JP7550745B2/ja active Active
- 2019-07-19 AU AU2019311233A patent/AU2019311233B2/en active Active
- 2019-07-19 SG SG11202013044PA patent/SG11202013044PA/en unknown
- 2019-07-19 CA CA3106858A patent/CA3106858A1/en active Pending
- 2019-07-19 CN CN201980049332.XA patent/CN112771072B/zh active Active
- 2019-07-19 WO PCT/EP2019/069541 patent/WO2020020783A1/en not_active Ceased
- 2019-07-19 MX MX2021000801A patent/MX2021000801A/es unknown
- 2019-07-19 KR KR1020217002155A patent/KR20210038549A/ko not_active Ceased
- 2019-07-19 BR BR112021000811A patent/BR112021000811A8/pt unknown
-
2021
- 2021-01-19 IL IL280290A patent/IL280290A/en unknown
-
2024
- 2024-04-19 JP JP2024068146A patent/JP2024099664A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3106858A1 (en) | 2020-01-30 |
| JP2024099664A (ja) | 2024-07-25 |
| CN112771072A (zh) | 2021-05-07 |
| BR112021000811A8 (pt) | 2022-10-18 |
| BR112021000811A2 (pt) | 2021-04-13 |
| JP7550745B2 (ja) | 2024-09-13 |
| SG11202013044PA (en) | 2021-02-25 |
| JP2021531013A (ja) | 2021-11-18 |
| AU2019311233B2 (en) | 2025-01-09 |
| US20210292386A1 (en) | 2021-09-23 |
| AU2019311233A1 (en) | 2021-01-21 |
| WO2020020783A1 (en) | 2020-01-30 |
| KR20210038549A (ko) | 2021-04-07 |
| CN112771072B (zh) | 2025-01-07 |
| IL280290A (en) | 2021-03-01 |
| EP3827014A1 (en) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000801A (es) | Agonistas de il2. | |
| WO2019191633A3 (en) | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof | |
| EA201290395A1 (ru) | Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций | |
| CY1113117T1 (el) | Ηlα-α*3303-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση η οποια περιλαμβανει αυτο το ιδιο | |
| PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| DE60332358D1 (de) | Protease-resistente modifizierte interferon alpha polypeptide | |
| WO2021222150A3 (en) | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications | |
| HUP0004560A2 (hu) | Törést gyógyító PTHrP analógok | |
| ATE549028T1 (de) | Stabile analoga von glp-1 | |
| EA202192555A1 (ru) | Комбинированная терапия для лечения рака | |
| ZA202208999B (en) | Biased il2 muteins methods and compositions | |
| JP2017513503A5 (es) | ||
| PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
| PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
| MX2020013296A (es) | Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas. | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| CL2012001656A1 (es) | Polipéptido de somatotropina bovina que comprende uno o mas aminoácidos no naturales y que estan ligados a un polimero soluble en agua. composicion farmaceutica que comprende dichos polipeptidos. | |
| JOP20220110A1 (ar) | ناهضات مستقبل npy2 | |
| MX2021015852A (es) | Agonistas de il2. | |
| EA200602257A1 (ru) | Стабилизированные жидкие препаративные формы интерферона | |
| MY167485A (en) | Recombinant human interferon-like proteins | |
| CR20230074A (es) | Agonistas del receptor npy2 solubles | |
| UA91820C2 (ru) | Терапевтическое применение вариантов хемокинов | |
| WO2004009625A3 (en) | PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF α-SYNUCLEIN-RELATED DISEASES |